Mercado global de terapia com bacteriófagos – Tendências da indústria e previsão para 2029

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado global de terapia com bacteriófagos – Tendências da indústria e previsão para 2029

  • Pharmaceutical
  • Upcoming Reports
  • May 2022
  • Global
  • 350 Páginas
  • Número de tabelas: 220
  • Número de figuras: 60

Global Bacteriophages Therapy Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Chart Image USD 39.80 Million USD 64.40 Million 2021 2029
Diagram Período de previsão
2022 –2029
Diagram Tamanho do mercado (ano base )
USD 39.80 Million
Diagram Tamanho do mercado ( Ano de previsão)
USD 64.40 Million
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Manequim1
  • Manequim2
  • Manequim3
  • Manequim4
  • Manequim5

>Mercado global de terapia com bacteriófagos, por alvo (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, outros), tipo (lítico, lisogénico), base (cultura de caldo estéril, base de gelatina solúvel em água), aplicação (disenteria bacteriana , infeções da pele) E mucosa nasal, infeção supurativa da pele, infeções pulmonares e pleurais, infeções de feridas pós-operatórias, outras), via de administração (oral, parentérica, retal, dérmica, outras), utentes finais (hospitais, clínicas especializadas, assistência domiciliária, outros), distribuição Canal (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros) – Tendências e Previsão do Setor até 2029

Bacteriophages Therapy Market

Análise de Mercado e Tamanho                              

A resistência aos antibióticos está a tornar-se mais comum em todo o mundo, o que está a aumentar a procura por alternativas eficazes. De acordo com o CDC, as infeções bacterianas resistentes aos antibióticos afetam aproximadamente 33.000 pessoas na Europa todos os anos. Prevê-se que a resistência aos antibióticos aumente globalmente, criando uma procura considerável de bacteriófagos. A terapia fágica é outro nome para a terapia bacteriófaga. Para tratar infeções bacterianas, são utilizados vírus. Os bacteriófagos são vírus bacterianos. Os fagos são vírus que matam bactérias e são inofensivos para as plantas, animais e humanos. Acredita-se que os bacteriófagos são os adversários naturais das bactérias. Os bacteriófagos podem ser encontrados em esgotos, água, solo e outros ambientes onde existam bactérias.

A Data Bridge Market Research analisa que o mercado da terapia com bacteriófagos foi avaliado em 39,80 milhões de dólares em 2021 e deverá atingir os 64,40 milhões de dólares até 2029, registando um CAGR de 6,20% durante o período previsto de 2022 a 2029. Além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge também inclui análise análise aprofundada de especialistas, epidemiologia do doente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito do Relatório e Segmentação de Mercado

Métrica de Reporte

Detalhes

Período de previsão

2022 a 2029

Ano base

2021

Anos históricos

2020 (Personalizável para 2014 - 2019)

Unidades quantitativas

Receita em milhões de dólares americanos, volumes em unidades, preços em dólares americanos

Segmentos abrangidos

Alvo (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, Outros), Tipo (Lítico, Lisogénico), Base (Cultura de Caldo Estéril, Base de Geleia Solúvel em Água), Aplicação (Disenteria Bacteriana, Infeções da Pele e Mucosa Nasal, Pele Supurativa Infecção, Infecções pulmonares e pleurais, Infecções de feridas pós-operatórias, Outros), Via de administração (oral, parentérica, rectal, dérmica, outros), Utentes finais (hospitais, clínicas especializadas, assistência domiciliária, outros), Canal de distribuição (farmácia hospitalar, retalho Farmácia, Farmácia Online, Outros)

Países abrangidos

EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão, Índia, Coreia do Sul, Singapura, Malásia , Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul

Atores do mercado abrangidos

Microgen (EUA), Micreos (Holanda), ATCC (EUA), Intralytix, Inc. (EUA), Adaptive Phage Therapeutics (EUA), Armata Pharmaceuticals Inc. (EUA), LOCUS BIOSCIENCES, INC. Inc. (EUA), Nextbiotics (EUA), Pherecydes Pharma (França), iNtODEWORLD. Inc. (EUA), Enbiotix (EUA), Fixed-Phage Limited (Reino Unido), Cytophage Technologies Inc. (Canadá), Eliava Bio Preparations LTD (Geórgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong ) , TechnoPhage (Portugal), Eligo Bioscience SA (França), BiomX Ltd. (Israel)

Oportunidades de Mercado

  • Aumento do número de atividades de investigação e desenvolvimento
  • Avanço tecnológico crescente

Definição de Mercado

Os bacteriófagos são vírus que matam e atacam exclusivamente bactérias. São uma das entidades biológicas mais frequentes capazes de combater e matar bactérias multirresistentes. Quando todos os outros antibióticos falharam no tratamento de uma infeção, os fagos podem eliminar as bactérias que causam a infeção, permitindo aos especialistas médicos salvar uma vida. Os bacteriófagos estão a ser considerados um substituto dos antibióticos. Os vírus são empregues nesta terapia para injetar o seu material genético nas bactérias e crescer utilizando a sua maquinaria hospedeira. Esta terapia fágica é utilizada no organismo dos doentes para curar ou prevenir doenças bacterianas. A terapia bacteriófaga é também importante nas disciplinas de biologia molecular e investigação tecnológica. Estas características alargam a possibilidade de desenvolvimento de medicamentos. Os bacteriófagos são também chamados de fagos.

Dinâmica do mercado da terapia com bacteriófagos

Motoristas

  • Elevada taxa de prevalência de doenças transmitidas por alimentos

O aumento da taxa de prevalência de doenças transmitidas por alimentos em todo o mundo atuará como um importante impulsionador que resultará na expansão da taxa de crescimento do mercado. As infeções transmitidas por alimentos estragados estão a tornar-se mais comuns. As bactérias e os vírus patogénicos estão presentes em alimentos estragados. Segundo a OMS, cerca de 600 milhões de pessoas (quase uma em cada dez pessoas no planeta) ficarão doentes e 420.000 morrerão em consequência de alimentos contaminados em 2019, resultando na perda de 33 milhões de anos de vida saudável (DALYs). Além disso, as crianças com menos de cinco anos são responsáveis ​​por 40% das doenças transmitidas por alimentos, com 125.000 mortes todos os anos. Este aspeto está a impulsionar o mercado de terapia com bacteriófagos.

  • Aumento do investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado da terapia com bacteriófagos é o aumento dos gastos em saúde, o que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de saúde através do aumento do financiamento, o que influenciará ainda mais a dinâmica do mercado.

  • Prevalência crescente de infeções resistentes a antibióticos

Espera-se que a crescente prevalência de infeções resistentes aos antibióticos aumente o crescimento do mercado. A crescente prevalência de infeções resistentes aos antimicrobianos resultou em maiores gastos em saúde para o seu tratamento e num aumento do número de mortes. De acordo com os Centros de Controlo e Prevenção de Doenças (CDC), aproximadamente 2 milhões de pessoas nos Estados Unidos contrairão uma infeção resistente aos antibióticos em 2019, com pelo menos 23.000 pessoas a morrerem por ano. De acordo com a Organização Mundial de Saúde, mais de 490.000 pessoas em todo o mundo foram infetadas com tuberculose multirresistente em 2016. Esta resistência aos medicamentos complica o tratamento de pessoas que sofrem de outras doenças, incluindo a malária e o VIH.

Além disso, um número crescente de iniciativas governamentais para sensibilizar e aumentar a população geriátrica resultará na expansão do mercado da terapia com bacteriófagos. Juntamente com isto, a mudança no estilo de vida das pessoas e o aumento do nível de rendimento disponível aumentarão a taxa de crescimento do mercado.

Oportunidades

  • Aumento do número de atividades de investigação e desenvolvimento       

Além disso, o crescimento do mercado é impulsionado pelo aumento do número de atividades de investigação e desenvolvimento. Isto proporcionará oportunidades benéficas para o crescimento do mercado da terapia com bacteriófagos. Por exemplo, em janeiro de 2019, a Food and Drug Administration dos EUA aprovou um pedido de médicos-cientistas da Faculdade de Medicina da Universidade da Califórnia em San Diego para realizar o primeiro ensaio clínico nos EUA de uma terapia baseada em bacteriófagos administrada por via intravenosa. A experiência planeada será realizada em parceria com a AmpliPhi Biosciences Corporation, uma empresa de biotecnologia sediada em San Diego.

Além disso, o crescimento do mercado é impulsionado pelos investimentos no desenvolvimento de tecnologias avançadas e no aumento do número de mercados emergentes. Estes fatores proporcionarão oportunidades benéficas para o crescimento do mercado da terapia com bacteriófagos.

Restrições/Desafios

Por outro lado, o elevado custo associado à terapia com bacteriófagos irá obstruir a taxa de crescimento do mercado da terapia com bacteriófagos durante o período previsto de 2022-2029. A falta de infraestruturas de saúde nas economias em desenvolvimento e o cenário regulamentar rigoroso desafiarão o mercado da terapia com bacteriófagos. Além disso, a falta de sensibilização entre as pessoas e a disponibilidade de alternativas irão restringir e impedir ainda mais a taxa de crescimento do mercado durante o período previsto de 2022-2029.

Este relatório de mercado de terapia com bacteriófagos fornece detalhes de novos desenvolvimentos recentes, regulamentos comerciais, análise de importação e exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsos de receita emergentes, alterações no mercado regulamentações, análise estratégica de crescimento de mercado, tamanho de mercado, crescimento de mercado de categorias, nichos de aplicação e dominância, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado . Para mais informações sobre o mercado da terapia com bacteriófagos, contacte a Data Bridge Market Research para obter um briefing de analista.

Análise epidemiológica do doente

O mercado de terapia com bacteriófagos também fornece análises de mercado detalhadas para análise de pacientes, prognóstico e curas. Prevalência, incidência, mortalidade e taxas de adesão são algumas das variáveis ​​de dados disponíveis no relatório. As análises de impacto direto ou indireto da epidemiologia no crescimento do mercado são analisadas para criar um modelo estatístico multivariado de coorte mais robusto para prever o mercado no período de crescimento.

Impacto da COVID-19 no mercado da terapia com bacteriófagos

A doença espalhou-se por mais de 100 países desde o surto viral da COVID-19, em dezembro de 2019, levando a Organização Mundial de Saúde a designá-la como emergência de saúde pública. Além disso, a pandemia da COVID-19 representou desafios significativos para as empresas no mercado mundial da terapia bacteriófaga em diversas frentes. O fornecimento de matérias-primas para a produção de formulações de medicamentos era uma grande dificuldade devido a inconsistências nas instalações de transporte. Além disso, devido ao aumento da população de doentes que sofriam de COVID-19 e outras condições fatais, os distribuidores de produtos enfrentavam uma procura irregular por parte dos retalhistas. A pandemia da COVID-19 interrompeu os ensaios clínicos nos Estados Unidos, afetando importantes participantes do setor. As licenças de pessoal, os protocolos de distanciamento social, as perdas financeiras e as preocupações com a segurança dos doentes impactaram as capacidades do local de investigação. Os patrocinadores, CROs e outras empresas de apoio ao desenvolvimento de medicamentos migraram para ambientes de trabalho remotos. Como resultado da pandemia da COVID-19, estima-se que 80% dos ensaios clínicos não relacionados com a COVID-19 foram interrompidos ou descontinuados.

Âmbito do mercado global de terapia com bacteriófagos

O mercado da terapia com bacteriófagos está segmentado com base no alvo, tipo, base, aplicação, via de administração, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de baixo crescimento nos setores e fornecerá aos utilizadores uma visão geral e informações valiosas do mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.

Objetivo

  • Escherichia coli
  • Estafilococo
  • Estreptococo
  • Pseudomonas
  • Salmonela
  • Outros

Tipo

  • Lítico
  • Lisogênico

Base

  • Cultura de caldo estéril
  • Base de gelatina solúvel em água

Aplicação

  • Disenteria bacteriana
  • Infeções da pele e da mucosa nasal
  • Infecção cutânea supurativa
  • Infecções pulmonares e pleurais
  • Infeções de feridas pós-operatórias
  • Outros

Via de Administração

  • Oral
  • Parenteral
  • Retal
  • Dérmico
  • Outros

Utilizadores finais

  • Hospitais
  • Clínicas especializadas
  • Assistência Domiciliária
  • Outros

Canal de Distribuição

  • Farmácia Hospitalar
  • Farmácia de retalho
  • Farmácia Online
  • Outros

Análise regional/perspetivas do mercado de terapia com bacteriófagos

O mercado da terapia com bacteriófagos é analisado e são fornecidos insights e tendências sobre o tamanho do mercado por país, alvo, tipo, base, aplicação, via de administração, utilizador final e canal de distribuição, conforme referenciado acima.

Os países abrangidos pelo relatório de mercado da terapia com bacteriófagos são os EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Países Baixos, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China , Japão, Índia , Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul

A América do Norte domina o mercado da terapia com bacteriófagos em termos de quota de mercado e receitas de mercado e continuará a aumentar o seu domínio durante o período previsto. Isto deve-se à recuperação imediata e ao efeito terapêutico proporcionados pelo bacteriófago lítico, e o aumento dos gastos em saúde impulsionará ainda mais a taxa de crescimento do mercado nesta região. Além disso, a presença de grandes players e o aumento da adoção de novas tecnologias impulsionará ainda mais a taxa de crescimento do mercado nesta região.

Prevê-se que a Ásia-Pacífico seja a região de crescimento mais rápido durante o período previsto de 2022-2029 devido ao aumento do investimento em I&D inovador para novos medicamentos nesta região. Além disso, o desenvolvimento da infra-estrutura de saúde e o aumento das iniciativas governamentais impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a montante e a jusante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas globais e os seus desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, ao impacto de tarifas domésticas e rotas comerciais são considerados ao fornecer uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado das terapias com bacteriófagos

The bacteriophages therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bacteriophages therapy market.

Some of the major players operating in the bacteriophages therapy market are:

  • Microgen (U.S.)
  • Micreos (Netherlands)
  • ATCC (U.S.)
  • Intralytix, Inc. (U.S.)
  • Adaptive Phage Therapeutics (U.S.)
  • Armata pharmaceuticals Inc. (U.S.)
  • LOCUS BIOSCIENCES, INC. (U.S.)
  • Delmont Laboratories, Inc. (U.S.)
  • Nextbiotics (U.S.)
  • Pherecydes Pharma (France)
  • iNtODEWORLD. Inc. (U.S.)
  • Enbiotix (U.S.)
  • Fixed-Phage Limited (U.K.)
  • Cytophage Technologies Inc. (Canada)
  • Eliava Bio Preparations LTD (Georgia)
  • Phagelux, Inc. (China)
  • InnoPhage, Ltd (Hong Kong)
  • TechnoPhage (Portugal)
  • Eligo Bioscience SA (France)
  • BiomX Ltd. (Israel)

SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL BACTERIOPHAGES THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TAREGET LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 GLOBAL BACTERIOPHAGES THERAPY MARKET: REGULATIONS

5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES

5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE

5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE

5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE

6 GLOBAL BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY

7 RESEARCH AND DEVELOPMENT ANALYSIS: GLOBAL BACTERIOPHAGES THERAPY MARKET

7.1 PIPELINE ANALYSIS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS

8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

8.1.3 INCREASING GOVERNMENT FUNDING

8.1.4 INCREASING PRIVATE SECTOR FUNDING

8.1.5 TECHNOLOGICAL ADVANCEMENTS

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY

8.2.2 LACK OF SKILLED PROFESSIONALS

8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY

8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE

8.3 OPPORTUNITIES

8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS

8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

8.3.3 INCREASING HEALTHCARE EXPENDITURE

8.4 CHALLENGES

8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY

8.4.2 LACK OF PROPER REGULATORY GUIDELINES

9 IMPACT OF COVID-19 ON GLOBAL BACTERIOPHAGES THERAPY MARKET

9.1 IMPACT ON THE PRICE

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY

9.4 STRATEGIC INITIATIVES BY MANUFACTURERS

9.5 CONCLUSION

10 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET

10.1 OVERVIEW

10.2 STAPHYLOCOCCUS

10.3 ESCHERICHIA COLI

10.4 PSEUDOMONAS

10.5 STREPTOCOCCUS

10.6 SALMONELLA

10.7 OTHERS

11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE

11.1 OVERVIEW

11.2 LYTIC

11.3 LYSOGENIC

12 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE

12.1 OVERVIEW

12.2 STERILE BROTH CULTURE

12.3 WATER-SOLUBLE JELLY BASE

13 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 POSTOPERATIVE WOUND INFECTIONS

13.3 INFECTIONS OF SKIN AND NASAL MUCOSA

13.4 BACTERIAL DYSENTERY

13.5 SUPPURATIVE SKIN INFECTIONS

13.6 LUNG AND PLEURAL INFECTION

13.7 OTHERS

14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.2.1 LIQUID

14.2.2 TABLET

14.3 DERMAL

14.4 PARENTERAL

14.4.1 INTRAVENOUSLY

14.4.2 INTRAPLEURAL INJECTIONS

14.5 OTHERS

15 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECILAITY CLINICS

15.4 ACADEMIC RESEARCH & INSTITUTES

15.5 OTHERS

16 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 THIRD PARTY DISTRIBUTORS

17 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION

17.1 OVERVIEW

17.2 NORTH AMERICA

17.2.1 U.S.

17.2.2 CANADA

17.3 EUROPE

17.3.1 GEORGIA

17.3.2 RUSSIA

17.3.3 BELGIUM

17.3.4 POLAND

17.3.5 FRANCE

17.3.6 NETHERLANDS

17.3.7 U.K.

17.3.8 ITALY

17.3.9 GERMANY

17.3.10 TURKEY

17.3.11 SWITZERLAND

17.3.12 REST OF EUROPE

17.4 MIDDLE EAST & AFRICA

17.4.1 SOUTH AFRICA

17.4.2 SAUDI ARABIA

17.4.3 ISRAEL

17.4.4 EGYPT

17.4.5 REST OF MIDDLE EAST & AFRICA

17.5 ASIA-PACIFIC

17.5.1 CHINA

17.5.2 JAPAN

17.5.3 INDIA

17.5.4 AUSTRALIA

17.5.5 SOUTH KOREA

17.5.6 SINGAPORE

17.5.7 REST OF ASIA-PACIFIC

17.6 SOUTH AMERICA

17.6.1 BRAZIL

17.6.2 ARGENTINA

17.6.3 REST OF SOUTH AMERICA

18 GLOBAL BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: GLOBAL

18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

18.3 COMPANY SHARE ANALYSIS: EUROPE

18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 MICROGEN

20.1.1 COMPANY SNAPSHOT

20.1.2 COMPANY SHARE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENTS

20.2 ADAPTIVE PHAGE THERAPEUTICS

20.2.1 COMPANY SNAPSHOT

20.2.2 COMPANY SHARE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENTS

20.3 PHAGELUX,INC

20.3.1 COMPANY SNAPSHOT

20.3.2 COMPANY SHARE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENTS

20.4 LOCUS BIOSCIENCES, INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 COMPANY SHARE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENTS

20.5 ATCC

20.5.1 COMPANY SNAPSHOT

20.5.2 COMPANY SHARE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENTS

20.6 INTRALYTIX, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENTS

20.7 MICREOS

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 PYLUM

20.8.1 COMPANY SNAPSHOT

20.8.2 TECHNOLOGY PORTFOLIO

20.8.3 RECENT DEVELOPMENTS

20.9 FIXED-PHAGE LIMITED

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENTS

20.1 ARMATA PHARMACEUTICALS, INC.

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENTS

20.11 ARTHUR ANDREW MEDICAL

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 CYTOPHAGE TECHNOLOGIES INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 ENBIOTIX, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENTS

20.14 INTODEWORLD, INC.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 NEXTBIOTICS

20.15.1 COMPANY SNAPSHOT

20.15.2 TECHNOLOGY PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.16 PHERECYDES PHARMA

20.16.1 COMPANY SNAPSHOT

20.16.2 PRODUCT PORTFOLIO

20.16.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Lista de Tabela

TABLE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 2 GLOBAL STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 GLOBAL ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 GLOBAL PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 GLOBAL STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 GLOBAL SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 GLOBAL LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 GLOBAL LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 12 GLOBAL STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 GLOBAL WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 24 GLOBAL DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 29 GLOBAL HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 GLOBAL SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 GLOBAL ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 34 GLOBAL DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 GLOBAL THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 51 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 52 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 61 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 62 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 EUROPE BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 66 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 67 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 EUROPE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 69 EUROPE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 70 EUROPE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 EUROPE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 EUROPE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 73 EUROPE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 74 EUROPE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 76 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 78 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 79 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 80 GEORGIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 GEORGIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 84 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 85 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 87 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 88 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 89 RUSSIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 90 RUSSIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 94 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 96 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 BELGIUM ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 99 BELGIUM PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 100 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 101 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 102 POLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 103 POLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 POLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 105 POLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 POLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 107 POLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 108 POLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 109 POLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 110 POLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 111 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 112 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 114 FRANCE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 FRANCE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 117 FRANCE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 118 FRANCE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 119 FRANCE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 120 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 121 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 123 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 124 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 125 NETHERLANDS ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 126 NETHERLANDS PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 127 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 128 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 129 U.K. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 130 U.K. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 U.K. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 132 U.K. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 133 U.K. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 134 U.K. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 135 U.K. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 136 U.K. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 U.K. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 138 ITALY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 139 ITALY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 ITALY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 141 ITALY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 142 ITALY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 143 ITALY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 144 ITALY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 145 ITALY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 ITALY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 148 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 GERMANY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 150 GERMANY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 GERMANY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 152 GERMANY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 153 GERMANY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 154 GERMANY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 155 GERMANY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 156 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 157 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 TURKEY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 159 TURKEY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 160 TURKEY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 TURKEY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 TURKEY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 163 TURKEY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 164 TURKEY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 165 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 166 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 168 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 169 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 170 SWITZERLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 171 SWITZERLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 172 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 173 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 174 REST OF EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 175 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 176 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 177 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 179 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 181 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 182 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 184 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 185 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 186 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 187 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 188 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 189 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 190 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 191 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 192 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 193 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 194 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 195 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 197 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 198 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 199 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 202 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 203 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 204 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 205 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 206 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 207 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 209 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 210 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 213 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 216 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 217 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 218 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 219 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 220 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 221 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 222 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 223 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 224 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 225 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 226 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 227 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 ASIA-PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 ASIA-PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 230 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 231 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 232 CHINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 233 CHINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 234 CHINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 235 CHINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 236 CHINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 237 CHINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 238 CHINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 239 CHINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 240 CHINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 241 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 242 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 JAPAN BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 244 JAPAN BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 245 JAPAN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 246 JAPAN ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 247 JAPAN PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 248 JAPAN BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 249 JAPAN BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 250 INDIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 251 INDIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 252 INDIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 253 INDIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 254 INDIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 255 INDIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 256 INDIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 257 INDIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 INDIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 259 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 260 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 262 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 263 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 264 AUSTRALIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 265 AUSTRALIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 266 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 268 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 269 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 271 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 272 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 273 SOUTH KOREA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 274 SOUTH KOREA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 275 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 277 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 278 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 279 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 280 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 281 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 282 SINGAPORE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 283 SINGAPORE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 284 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 286 REST OF ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 287 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 288 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 289 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 291 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 292 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 293 SOUTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 294 SOUTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 295 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 296 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 297 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 298 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 299 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 300 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 301 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 302 BRAZIL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 303 BRAZIL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 304 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 305 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 306 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 307 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 309 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 310 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 311 ARGENTINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 312 ARGENTINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 313 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 314 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 315 REST OF SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

Lista de Figura

FIGURE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 2 GLOBAL BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL BACTERIOPHAGES THERAPY MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR STEM CELL MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BACTERIOPHAGES THERAPY MARKET

FIGURE 16 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020

FIGURE 17 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)

FIGURE 18 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)

FIGURE 19 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE

FIGURE 20 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020

FIGURE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020

FIGURE 25 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)

FIGURE 26 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)

FIGURE 27 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE

FIGURE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020

FIGURE 29 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 30 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 31 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 32 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 34 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 35 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020

FIGURE 37 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 45 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020)

FIGURE 46 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2021 & 2028)

FIGURE 47 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020 & 2028)

FIGURE 48 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 49 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 50 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 51 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 52 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 53 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 54 EUROPE BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 55 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 56 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 57 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 58 EUROPE BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 59 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 60 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 61 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 62 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 63 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 64 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 65 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 66 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 67 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 68 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 69 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 70 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 71 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 72 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 73 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 74 GLOBAL BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 75 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 76 EUROPE BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 77 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Bacteriophages Therapy Market will be worth USD 64.40 million by 2029 during the forecast period.
The Bacteriophages Therapy Market growth rate is 6.20% during the forecast period.
High prevalence rate of foodborne diseases, Increasing investment for healthcare infrastructure, and the Growing prevalence of antibiotic-resistant infections are the growth drivers of the Bacteriophages Therapy Market.
The target, type, base, application, route of administration, end-user, and distribution channel are the factors on which the Bacteriophages Therapy Market research is based.
Major companies in the Bacteriophages Therapy Market are Microgen (U.S.), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata pharmaceuticals Inc. (U.S.),LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Bio Preparations LTD (Georgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel).
Testimonial